Answers are grounded in this paper and cite their sources.
This is the longest follow-up from a phase III trial of BRAF/MEK inhibitor combination in BRAF V600E/K-mutant metastatic melanoma. Safety results were consistent with the known tolerability profile of encorafenib plus binimetinib. Results support the long-term efficacy and known safety of encorafenib plus binimetinib in this population and provide new insights on long-term responders. Interactive data visualization is available at the COLUMBUS dashboard (https://clinical-trials.dimensions.ai/columbus7/).
No takes yet. Share an insight, caveat, or question.
Schadendorf et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: